Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIA study of ALLOB osteoblastic cell implantation in multiple non-infected delayed-union fractures
2015-000650-38Phase 2Completed
- Sponsor
- BioSenic
- Start
- Mar 2015
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allogeneic osteoblastic cells in delayed bone healing and bone fracture (Fx), sponsored by BioSenic. Primary endpoints: Safety endpoints and Efficacy endpoints. Started Mar 2015; status: completed.
02
Drugs
allogeneic osteoblastic cells
03
Conditions
delayed bone healingbone fracture (Fx)
Beyond the preview
Go deeper on 2015-000650-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000650-38.